RE:RE:RE:RE:TesamorelinAkero was unfortunate for the overall NASH market, but does mean solutions beyond Madrigal may still have a market. Althought, they may get it back on track. Back in those days of all the expert talking heads, they all agreed there will be multiple therapies because the disease has multiple pathways. Some will work on certain types better than others, and combos may be tried. That's still out there. But it does remind me of what qwerty always pointed out --the placebo effect in these NASH trials is powerful, likely because the patients also get diet/exercise advice. Madrigal did a trial where they compared some who got that advice and some who didn't I think. But the 14% placebo response from Akero sunk their statistical significance, at least so far. I'm sure they'll keep going and hope to move it back to some significance level.